Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
21.80
+1.64 (8.13%)
At close: Jul 9, 2026, 4:00 PM EDT
22.37
+0.57 (2.61%)
Pre-market: Jul 10, 2026, 8:18 AM EDT
Adaptive Biotechnologies Employees
Adaptive Biotechnologies had 624 employees as of December 31, 2025. The number of employees increased by 5 or 0.81% compared to the previous year.
Employees
624
Change (1Y)
5
Growth (1Y)
0.81%
Revenue / Employee
$473,409
Profits / Employee
-$79,615
Market Cap
3.49B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 624 | 5 | 0.81% |
| Dec 31, 2024 | 619 | -90 | -12.69% |
| Dec 31, 2023 | 709 | -81 | -10.25% |
| Dec 31, 2022 | 790 | -68 | -7.93% |
| Dec 31, 2021 | 858 | 236 | 37.94% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| RadNet | 9,276 |
| Qiagen | 5,700 |
| Sotera Health Company | 3,000 |
| NeoGenomics | 2,500 |
| GeneDx Holdings | 1,300 |
| Twist Bioscience | 979 |
| GRAIL | 910 |
| CareDx | 765 |
ADPT News
- 16 hours ago - Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026 - GlobeNewsWire
- 1 day ago - Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley - TheFly
- 11 days ago - Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim - TheFly
- 23 days ago - Adaptive Biotechnologies prices $300M convertible senior note offering - TheFly
- 23 days ago - Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering - GlobeNewsWire
- 23 days ago - Adaptive Biotechnologies management to meet with Craig-Hallum - TheFly
- 24 days ago - Adaptive Biotechnologies offers to sell $250M in 2031 convertible senior notes - TheFly
- 24 days ago - Adaptive Biotechnologies plans separation of immune medicine platform - Reuters